Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 7 Feb 2012 |
| Notice to the Annual General Meeting of Orion Corporation | 7 Feb 2012 |
| Orion Group Financial Statement Release for 2011 | 7 Feb 2012 |
| Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2012 AGM of Orion Corporation | 30 Jan 2012 |
| Orion invites analysts and media to Financial Statement Release conference on Tuesday 7 February 2012 | 20 Jan 2012 |